A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France

NCT ID: NCT03757013

Last Updated: 2021-12-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

453 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-09-25

Study Completion Date

2021-09-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

REALIZE study will include a representative sample of 500 patients with moderate to severe plaque psoriasis for whom the treating dermatologist has decided to begin apremilast treatment in accordance with the local label reimbursement criteria. Patients may be enrolled into the study up to 4 weeks after starting the study treatment.

REALIZE is a longitudinal, multicenter, observational study under real life settings in patients with moderate to severe chronic plaque psoriasis after failure or contra-indication or intolerance to other systemic therapy including ciclosporin, methotrexate, or phototherapy UVA + psoralen (PUVA therapy).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Eligible patients will be identified and invited to enroll from approximately 100 dermatologists in France practicing in public hospitals (or private clinics) or private practice. Patients will be followed over 12 months after initiation of apremilast or until discontinuation of apremilast whatever the earlier. Given the observational nature of the study, apremilast dosing and duration will be at the sole discretion of the treating dermatologist, in accordance with the local label and daily clinical practice. Patient care will follow routine clinical practice, involving regular follow-up visits, without any mandatory visit. In daily practice, patients are usually seen by their treating dermatologist every 6 months. In this study, patients will be followed up at most 12 months after apremilast initiation.

During this study, it is expected to collect data at inclusion (enrolment visit) and around 6 months and 12 months after apremilast initiation, on electronic case report forms (eCRF) by the dermatologist after performing a visit around 6 and 12 months to evaluate the treatment response following the apremilast initiation.

Due to the observational nature of the study, the study protocol does not require any specific tests or additional examinations. All assessments will be recorded in the electronic case report form (eCRF) according to the normal practice of the treating dermatologist. Self-questionnaires will be filled by the patient when visiting his/her dermatologist.

Total duration of the study is 2 years and 6 months, which includes an enrollment period of 1 year and 6 months and a follow up period of up to 1 year.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriasis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Plaque Psoriasis Apremilast France CC-10004

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients treated with Apremilast

Patients with moderate to severe chronic plaque psoriasis after failure or contra-indication or intolerance to other systemic therapy including ciclosporin, methotrexate, or phototherapy UVA + psoralen (PUVA therapy).

Apremilast

Intervention Type DRUG

Apremilast

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Apremilast

Apremilast

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female aged at least 18 years
* Patient with a diagnosis of stable moderate to severe chronic plaque psoriasis
* For whom the treating dermatologist has made the decision to initiate apremilast treatment in accordance with the local label and reimbursement criteria i.e. a history of failure or contra-indication or intolerance to other systemic therapy including ciclosporin, methotrexate, or phototherapy UVA + psoralen (PUVA therapy)
* Patient having started apremilast up to 4 weeks before the enrolment visit for treatment of moderate to severe chronic plaque psoriasis even if apremilast has been stopped before inclusion in the study
* Patient literate and willing to fill in questionnaires
* Non-opposition form signed by the investigator indicating that the patient received information about the study, and orally agreed.

Exclusion Criteria

* Patient who refuses to participate in the study or is unable to give his/her oral consent
* Patient having participated in an interventional study in the last 30 days
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Amgen

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

MD

Role: STUDY_DIRECTOR

Amgen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Private Practice, Amiens

Amiens, , France

Site Status

Saint-Joseph Clinic, Angouleme

Angoulême, , France

Site Status

Private Practice, Antibes

Antibes, , France

Site Status

Private Practice 2, Antony

Antony, , France

Site Status

Private Practice 2, Arcachon

Arcachon, , France

Site Status

Private Practice, Argenteuil

Argenteuil, , France

Site Status

Private Practice, Aubière

Aubière, , France

Site Status

Private Practice, Auch

Auch, , France

Site Status

Auxerre Hospital

Auxerre, , France

Site Status

Henri Duffaut Hospital

Avignon, , France

Site Status

Private Practice, Besançon

Besançon, , France

Site Status

Reims-Bezannes Polyclinic 2

Bezannes, , France

Site Status

Reims-Bezannes Polyclinic 3

Bezannes, , France

Site Status

Reims-Bezannes Polyclinic

Bezannes, , France

Site Status

Private Practice, Bègles

Bègles, , France

Site Status

Private Practice, Biarritz

Biarritz, , France

Site Status

Private Practice, Bordeaux

Bordeaux, , France

Site Status

Docteur Duchenne Hospital 2

Boulogne-sur-Mer, , France

Site Status

Docteur Duchenne Hospital

Boulogne-sur-Mer, , France

Site Status

Private Practice 2, Caen

Caen, , France

Site Status

Private Practice 3, Caen

Caen, , France

Site Status

Private Practice, Caen

Caen, , France

Site Status

Private Practice, Cannes

Cannes, , France

Site Status

Private Practice, Chamalières

Chamalières, , France

Site Status

Métropole Savoie Hospital

Chambéry, , France

Site Status

Trousseau Hospital

Chambray-lès-Tours, , France

Site Status

Private Practice 2, Chartres

Chartres, , France

Site Status

Private Practice, Chartres

Chartres, , France

Site Status

Private Practice 2, Chalons-en-Champagne

Châlons-en-Champagne, , France

Site Status

Private Practice, Chalons-en-Champagne

Châlons-en-Champagne, , France

Site Status

Chalons-en-Champagne Hospital

Châlons-en-Champagne, , France

Site Status

New Sud Francilien Hospital

Corbeil-Essonnes, , France

Site Status

GH de Dax, Dax

Dax, , France

Site Status

Private Practice 2, Dijon

Dijon, , France

Site Status

Private Practice 3, Dijon

Dijon, , France

Site Status

Private Practice, Dijon

Dijon, , France

Site Status

Private Practice, Dole

Dole, , France

Site Status

Victor Jousselin Hospital

Dreux, , France

Site Status

Private Practice, Essey-les-Nancy

Essey-lès-Nancy, , France

Site Status

Emile Durkheim Hospital - Saint Jean Health Center

Épinal, , France

Site Status

Golfe de St-Tropez Clinic

Gassin, , France

Site Status

Private Practice 2, Joue les Tours

Joué-lès-Tours, , France

Site Status

Private Practice 3, Joue les Tours

Joué-lès-Tours, , France

Site Status

Private Practice, Joue les Tours

Joué-lès-Tours, , France

Site Status

Private Practice, L'Union

L'Union, , France

Site Status

Private Practice 2, La Teste-de-Buch

La Teste-de-Buch, , France

Site Status

Private Practice, La Teste-de-Buch

La Teste-de-Buch, , France

Site Status

Private Practice, La Valette du Var

La Valette-du-Var, , France

Site Status

Private Practice, La Varenne Saint Hilaire

La Varenne-Saint-Hilaire, , France

Site Status

Private Practice 2, Laval

Laval, , France

Site Status

Private Practice, Laval

Laval, , France

Site Status

Private Practice, Le-Bourget-du-Lac

Le Bourget-du-Lac, , France

Site Status

Private Practice, Le Mans

Le Mans, , France

Site Status

Mans Hospital 2

Le Mans, , France

Site Status

Mans Hospital

Le Mans, , France

Site Status

Private Practice, Lille

Lille, , France

Site Status

Private Practice 2, Luce

Lucé, , France

Site Status

Private Practice, Luce

Lucé, , France

Site Status

Private Practice, Lyon

Lyon, , France

Site Status

Edouard Herriot Hospital

Lyon, , France

Site Status

Private Practice 2, Lyon

Lyon, , France

Site Status

Private Practice 4, Lyon

Lyon, , France

Site Status

Private Practice, Martigues

Martigues, , France

Site Status

Annecy Genevois Hospital, Metz Tessy

Metz-Tessy, , France

Site Status

Private Practice, Meudon-la-Forêt

Meudon-la-Forêt, , France

Site Status

Private Practice, Muret

Muret, , France

Site Status

Hotel Dieu Hospital, Dermatologic Clinic

Nantes, , France

Site Status

Private Practice, Narbonne

Narbonne, , France

Site Status

Private Practice, Nevers

Nevers, , France

Site Status

Private Practice 2, Nice

Nice, , France

Site Status

Private Practice 3, Nice

Nice, , France

Site Status

Private Practice, Nogent-Le-Rotrou

Nogent-le-Rotrou, , France

Site Status

Private Practice, Orléans

Orléans, , France

Site Status

Private Practice, Paris

Paris, , France

Site Status

Private Practice 2, Paris

Paris, , France

Site Status

Private Practice 3, Paris

Paris, , France

Site Status

Private Practice 4, Paris

Paris, , France

Site Status

Private Practice 5, Paris

Paris, , France

Site Status

Private Practice, Pontarlier

Pontarlier, , France

Site Status

Private Practice, Pontoise

Pontoise, , France

Site Status

Private Practice, Quimper

Quimper, , France

Site Status

CHI de Cornouaille - Laennec

Quimper, , France

Site Status

Mathilde II Clinic

Rouen, , France

Site Status

Private Practice, Saint-Etienne

Saint-Etienne, , France

Site Status

Saint-Etienne Hospital

Saint-Priest-en-Jarez, , France

Site Status

Private Practice, Torcy

Torcy, , France

Site Status

BCRM Toulon - HIA Saint-Anne

Toulon, , France

Site Status

Private Practice, Toulouse

Toulouse, , France

Site Status

Nord Franche-Comté Hospital

Trévenans, , France

Site Status

Valence Hospital 2

Valence, , France

Site Status

Valence Hospital 3

Valence, , France

Site Status

Valence Hospital

Valence, , France

Site Status

Jacques Lacarin Hospital

Vichy, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Jullien D, Richard MA, Halioua B, Bessette C, Derancourt C, Bouloc A. The Needs of Patients with Psoriasis and Benefits of Apremilast in French Clinical Practice: Results from the Observational REALIZE Study. Dermatol Ther (Heidelb). 2023 Jun;13(6):1361-1376. doi: 10.1007/s13555-023-00933-z. Epub 2023 May 19.

Reference Type DERIVED
PMID: 37204608 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.amgentrials.com

AmgenTrials clinical trials website

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

U1111-1218-9791

Identifier Type: REGISTRY

Identifier Source: secondary_id

CC-10004-PSOR-021

Identifier Type: -

Identifier Source: org_study_id